RT Journal Article
T1 Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma.
A1 Chen-Liang, Tzu-Hua
A1 Martín-Santos, Taida
A1 Jerez, Andrés
A1 Rodríguez-García, Guillermo
A1 Senent, Leonor
A1 Martínez-Millán, Cristina
A1 Muiña, Begoña
A1 Orero, Mayte
A1 Teruel, Anabel
A1 Martín, Alejandro
A1 Gómez-Espuch, Joaquín
A1 Kennedy, Kyra
A1 Benet, Carmen
A1 Raya, José María
A1 Fernández-González, Marta
A1 de la Cruz, Fátima
A1 Guinot, Marta
A1 Villegas, Carolina
A1 Ballester, Isabel
A1 Baile, Mónica
A1 Moya, María
A1 López-Jiménez, Javier
A1 Frutos, Laura
A1 Navarro, José Luis
A1 Uña, Jon
A1 Fernández-López, Rosa
A1 Igua, Carolina
A1 Contreras, José
A1 Sánchez-Vañó, Raquel
A1 Cozar, María Del Puig
A1 Tamayo, Pilar
A1 Mucientes, Jorge
A1 Sánchez-Blanco, José Javier
A1 Pérez-Ceballos, Elena
A1 Ortuño, Francisco José
K1 Bone marrow biopsy
K1 PET/CT
K1 diffuse large B-cell lymphoma
K1 outcomes research
AB Several studies have reported uneven results when evaluating the prognostic value of bone marrow biopsy (BMB) and PET/CT as part of the staging of diffuse large B-cell lymphoma (DLBCL). The heterogeneity of the inclusion criteria and not taking into account selection and collinearity biases in the analysis models might explain part of these discrepancies. To address this issue we have carried a retrospective multicenter study including 268 DLBCL patients with a BMB and a PET/CT available at diagnosis where we estimated both the prognosis impact and the diagnostic accuracy of each technique. Only patients treated with R-CHOP/21 as first line (n = 203) were included in the survival analysis. With a median follow-up of 25 months the estimated 3-year progression-free survival (PFS) and overall survival (OS) were 76.3% and 82.7% respectively. In a multivariate analysis designed to avoid a collinearity bias with IPI categories, BMB-BMI [bone marrow involvement](+) (HR: 3.6) and ECOG PS > 1 (HR: 2.9) were independently associated with a shorter PFS and three factors, age >60 years old (HR: 2.4), ECOG PS >1 (HR: 2.4), and abnormally elevated B2-microglobulin levels (HR: 2.2) were independently associated with a shorter OS. In our DLBCL cohort, treated with a uniform first-line chemotherapy regimen, BMI by BMB complemented performance status in predicting those patients with a higher risk for relapse or progression. In this cohort BMI by PET/CT could not independently predict a shorter PFS and/or OS.
YR 2017
FD 2017-09-27
LK http://hdl.handle.net/10668/11625
UL http://hdl.handle.net/10668/11625
LA en
DS RISalud
RD Apr 12, 2025